Surface Oncology akcijos akcijų analizė | Akcijų kaina | Naujienos | SURF | US86877M2098 | A2JJ8Q | 2025 m. spalis

Data	Surface Oncology Akcijų kaina
2023-09-12	0 undefined
2023-09-12	1,07 undefined
2023-09-11	1,07 undefined

Data	Surface Oncology Pajamos	Surface Oncology EBIT	Surface Oncology Pelnas
2028e	240,38 mln. undefined	0 undefined	40,95 mln. undefined
2027e	87,96 mln. undefined	−44,03 mln. undefined	−41,14 mln. undefined
2026e	25,71 mln. undefined	−86,87 mln. undefined	−55,55 mln. undefined
2025e	7,95 mln. undefined	−88,41 mln. undefined	−47,69 mln. undefined
2024e	0 undefined	−92,32 mln. undefined	−88,73 mln. undefined
2023e	0 undefined	−83,74 mln. undefined	−84,18 mln. undefined
2022	30,00 mln. undefined	−61,87 mln. undefined	−63,59 mln. undefined
2021	2,69 mln. undefined	−76,01 mln. undefined	−78,49 mln. undefined
2020	126,20 mln. undefined	61,50 mln. undefined	59,30 mln. undefined
2019	15,40 mln. undefined	−57,40 mln. undefined	−54,80 mln. undefined
2018	59,40 mln. undefined	−9,20 mln. undefined	−6,60 mln. undefined
2017	12,80 mln. undefined	−46,00 mln. undefined	−45,40 mln. undefined
2016	6,60 mln. undefined	−18,10 mln. undefined	−17,50 mln. undefined

2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e	2026e	2027e	2028e
6,00	12,00	59,00	15,00	126,00	2,00	30,00	0	0	7,00	25,00	87,00	240,00
-	100,00	391,67	−74,58	740,00	−98,41	1 400,00	-	-	-	257,14	248,00	175,86
-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0
−17,00	−45,00	−6,00	−54,00	59,00	−78,00	−63,00	−84,00	−88,00	−47,00	−55,00	−41,00	40,00
-	164,71	−86,67	800,00	−209,26	−232,20	−19,23	33,33	4,76	−46,59	17,02	−25,45	−197,56
26,50	26,50	20,00	27,90	38,10	44,24	55,76	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-

2016	2017	2018	2019	2020	2021	2022

79,20	63,30	158,80	105,20	175,10	154,15	124,82
0	0	0	0	2,60	0,52	0
0	0	0	0	0	247,00	197,00
0	0	0	0	0	0	0
1,00	1,10	4,50	2,40	2,80	2,43	4,12
80,20	64,40	163,30	107,60	180,50	157,35	129,14
3,90	7,30	8,20	22,10	34,60	31,52	29,17
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
1,10	2,80	1,20	1,60	2,10	1,98	1,60
5,00	10,10	9,40	23,70	36,70	33,50	30,77
85,20	74,50	172,70	131,30	217,20	190,85	159,91

48,50	48,50	0	0	0	0,01	0,01
2,00	6,90	169,80	178,20	218,00	259,86	298,74
−28,60	−73,90	−66,80	−121,60	−62,30	−140,74	−204,33
−400,00	−200,00	−100,00	100,00	0	−221,00	−1 015,00
0	0	0	0	0	0	0
21,50	−18,70	102,90	56,70	155,70	118,90	93,40
6,30	6,70	3,40	3,40	1,70	1,55	0,26
2,80	5,80	8,30	10,20	14,90	15,24	13,86
7,10	10,90	15,50	5,70	1,00	3,24	2,15
0	0	0	0	0	0	0
0	0	0	0	0	0	0
16,20	23,40	27,20	19,30	17,60	20,02	16,26
0	0	0	5,10	14,80	25,02	25,59
0	0	0	0	0	0	0
60,40	76,90	44,00	50,60	29,00	26,91	24,66
60,40	76,90	44,00	55,70	43,80	51,92	50,25
76,60	100,30	71,20	75,00	61,40	71,95	66,51
98,10	81,60	174,10	131,70	217,10	190,85	159,91

2016	2017	2018	2019	2020	2021	2022
−17,00	−45,00	−6,00	−54,00	59,00	−78,00	−63,00
0	0	1 000,00	1 000,00	1 000,00	1 000,00	1 000,00
0	0	0	0	0	0	0
58,00	26,00	−12,00	−14,00	−42,00	2,00	−7,00
0	5,00	4,00	7,00	11,00	12,00	10,00
0	0	0	0	1,00	1,00	2,00
3,00	7,00	0	0	0	0	0
41,00	−12,00	−13,00	−60,00	30,00	−62,00	−59,00
0	−1,00	−2,00	−1,00	0	0	0
−69,00	25,00	−36,00	16,00	58,00	−99,00	22,00
−69,00	27,00	−34,00	18,00	58,00	−99,00	23,00
0	0	0	0	0	0	0
0	0	0	7,00	10,00	10,00	0
25,00	0	100,00	0	30,00	31,00	31,00
25,00	−1,00	110,00	7,00	40,00	42,00	31,00
0	−1,00	9,00	0	0	0	0
0	0	0	0	0	0	0
−2,00	12,00	60,00	−35,00	128,00	−119,00	−5,00
40,57	−14,39	−15,24	−61,68	29,96	−62,46	−60,05
0	0	0	0	0	0	0

Surface Oncology Bruto marža	Surface Oncology EBIT marža	Surface Oncology Pelnas-martža
2028e	0 %	17,04 %
2027e	−50,06 %	−46,77 %
2026e	−337,94 %	−216,09 %
2025e	−1 112,74 %	−600,26 %
2024e	0 %	0 %
2023e	0 %	0 %
2022	−206,23 %	−211,95 %
2021	−2 828,92 %	−2 920,92 %
2020	48,73 %	46,99 %
2019	−372,73 %	−355,84 %
2018	−15,49 %	−11,11 %
2017	−359,38 %	−354,69 %
2016	−274,24 %	−265,15 %

Data	Surface Oncology Pardavimai vienai akcijai	Surface Oncology EBIT vienai akcijai	Surface Oncology Pelnas vienai akcijai
2028e	4,31 undefined	0 undefined	0,73 undefined
2027e	1,58 undefined	0 undefined	−0,74 undefined
2026e	0,46 undefined	0 undefined	−1,00 undefined
2025e	0,14 undefined	0 undefined	−0,86 undefined
2024e	0 undefined	0 undefined	−1,59 undefined
2023e	0 undefined	0 undefined	−1,51 undefined
2022	0,54 undefined	−1,11 undefined	−1,14 undefined
2021	0,06 undefined	−1,72 undefined	−1,77 undefined
2020	3,31 undefined	1,61 undefined	1,56 undefined
2019	0,55 undefined	−2,06 undefined	−1,96 undefined
2018	2,97 undefined	−0,46 undefined	−0,33 undefined
2017	0,48 undefined	−1,74 undefined	−1,71 undefined
2016	0,25 undefined	−0,68 undefined	−0,66 undefined

Segmente	2020
License	87,57 mln. USD
Supply Services	2,57 mln. USD

Data	EPS-prognozė	EPS-Faktinis	Pranešimo ketvirtis
2023-06-30	−0,34	−0,46 (−33,41 %)	2023 Q2
2023-03-31	−0,37	−0,33 (10,13 %)	2023 Q1
2022-12-31	−0,34	−0,35 (−3,98 %)	2022 Q4
2022-09-30	−0,48	−0,39 (18,07 %)	2022 Q3
2022-06-30	−0,47	−0,46 (1,60 %)	2022 Q2
2022-03-31	−0,29	0,13 (144,72 %)	2022 Q1
2021-12-31	−0,15	−0,52 (−236,13 %)	2021 Q4
2021-09-30	−0,41	−0,44 (−6,95 %)	2021 Q3
2021-06-30	−0,36	−0,44 (−22,09 %)	2021 Q2
2021-03-31	−0,42	−0,37 (11,10 %)	2021 Q1
2020-12-31	0,22	1,56 (601,44 %)	2020 Q4
2020-09-30	−0,40	−0,39 (2,96 %)	2020 Q3
2020-06-30	−0,49	−0,44 (10,75 %)	2020 Q2
2020-03-31	0,44	0,74 (70,04 %)	2020 Q1
2019-12-31	−0,59	−0,57 (3,65 %)	2019 Q4
2019-09-30	−0,59	−0,61 (−3,11 %)	2019 Q3
2019-06-30	−0,62	−0,64 (−3,43 %)	2019 Q2
2019-03-31	−0,46	−0,15 (67,68 %)	2019 Q1
2018-12-31	−0,69	−0,17 (75,25 %)	2018 Q4
2018-09-30	−0,69	−0,62 (10,61 %)	2018 Q3
2018-06-30	−0,77	−0,73 (5,21 %)	2018 Q2
2018-03-31	7,58	7,55 (−0,38 %)	2018 Q1

%	Pavadinimas	Akcijos	Pokytis	Data
9,98401 %	ARK Investment Management LLC	5 567 224	−468 467	2022-12-31
7,03840 %	EcoR1 Capital, LLC	3 924 713	0	2022-12-31
5,28224 %	Atlas Venture	2 945 453	0	2022-12-31
4,14137 %	The Vanguard Group, Inc.	2 309 286	816	2022-12-31
2,85860 %	Lilly Ventures	1 593 997	−1 853 820	2021-12-31
1,95898 %	Acadian Asset Management LLC	1 092 356	191 527	2022-12-31
1,94483 %	Goldman Sachs & Company, Inc.	1 084 467	−183 780	2022-12-31
1,92250 %	Nikko Asset Management Co., Ltd.	1 072 013	−32 217	2022-12-31
1,87613 %	Citi Investment Research (US)	1 046 157	−615	2022-12-31
1,40420 %	Dafna Capital Management, LLC	783 000	−317 000	2022-12-31
1,28073 %	Renaissance Technologies LLC	714 155	−271 188	2022-12-31
1,19330 %	Laurion Capital Management LP	665 400	0	2022-12-31
1,09611 %	Citadel Advisors LLC	611 207	−780 029	2022-12-31
1,02684 %	BlackRock Institutional Trust Company, N.A.	572 582	−334 317	2022-12-31
0,77051 %	Tang Capital Management, LLC	429 647	429 647	2022-12-31
0,75218 %	Stifel Nicolaus Investment Advisors	419 425	−10 940	2022-12-31
0,74473 %	Millennium Management LLC	415 270	41 760	2022-12-31
0,69279 %	Geode Capital Management, L.L.C.	386 312	13 698	2022-12-31
0,62767 %	Macquarie Investment Management	350 000	0	2022-12-31
0,50744 %	Knights of Columbus	282 953	−321	2022-12-31
0,49569 %	GSA Capital Partners LLP	276 403	156 020	2022-12-31
0,41820 %	Fidelity Management & Research Company LLC	233 193	−140 453	2022-12-31
0,36237 %	Dimensional Fund Advisors, L.P.	202 064	0	2022-12-31
0,32922 %	XTX Markets LLC	183 579	−182 642	2022-12-31
0,30768 %	State Street Global Advisors (US)	171 566	0	2022-12-31
0,30577 %	ACT Capital Management, L.L.C.	170 500	0	2022-09-30
0,28245 %	Bridgeway Capital Management, LLC	157 500	−25 000	2022-12-31
0,25863 %	Kingsbury Capital Investment Advisors, LLC	144 217	59 051	2022-09-30
0,23595 %	Jane Street Capital, L.L.C.	131 569	131 569	2022-12-31
0,23174 %	Goater (J Jeffrey)	129 222	129 222	2022-04-11
0,21762 %	Newton Investment Management North America, LLC	121 350	0	2022-12-31
0,20790 %	Boston Advisors, LLC	115 930	0	2023-01-31
0,19969 %	Fees (Jessica)	111 349	−5 980	2022-08-03
0,19893 %	Marshall Wace LLP	110 928	−96 025	2022-12-31
0,19444 %	CornerCap Investment Counsel, Inc.	108 424	0	2022-12-31
0,19246 %	Barclays Bank PLC	107 317	−310 448	2022-12-31
0,17353 %	BlackRock Financial Management, Inc.	96 764	0	2022-12-31
0,13710 %	Two Sigma Investments, LP	76 451	−122 844	2022-12-31
0,11362 %	Forefront Analytics, LLC	63 356	−3 482	2022-12-31
0,11147 %	Arete Wealth Advisors, LLC	62 156	4 966	2022-12-31
0,10717 %	Northern Trust Investments, Inc.	59 762	0	2022-12-31
0,10287 %	Franklin Advisers, Inc.	57 360	0	2022-12-31
0,09854 %	QS Investors, LLC	54 947	0	2022-12-31
0,09626 %	Nogelo (Liisa I)	53 677	−26 325	2021-07-21
0,09367 %	Ergoteles Capital	52 234	52 234	2022-12-31
0,08934 %	Susquehanna International Group, LLP	49 815	25 903	2022-12-31
0,08825 %	Palombella (Vito J)	49 212	−4 463	2022-08-03
0,08151 %	Sigal (Charles Elliott)	45 453	0	2022-04-11
0,07874 %	Ross Robert W	43 906	−10 594	2022-08-03
0,07532 %	Eagle Rock Investment Company, LLC	42 000	20 000	2022-12-31
0,07173 %	Credit Suisse Asset Management	40 000	0	2022-12-31
0,06970 %	Numeric Investors LLC	38 864	25 464	2022-12-31
0,06806 %	International Assets Investment Management, LLC	37 950	3 150	2022-09-30
0,06241 %	Adams (Chandra)	34 800	34 800	2022-10-27
0,05922 %	Dimensional Fund Advisors, Ltd.	33 023	0	2023-01-31
0,05797 %	Rath (Henry C)	32 324	−5 676	2022-08-03
0,05629 %	Morgan Stanley Smith Barney LLC	31 386	−12 041	2022-12-31
0,04827 %	Emerge Canada Inc	26 916	−3 376	2023-01-31
0,04744 %	KeyBanc Capital Markets	26 455	0	2022-12-31
0,04614 %	O'Neill (Alison)	25 728	−4 463	2022-08-03
0,04385 %	BofA Global Research (US)	24 451	−39 375	2022-12-31
0,04169 %	Group One Trading, L.P.	23 245	−13 374	2022-12-31
0,04089 %	RBC Dominion Securities, Inc.	22 800	−100 540	2022-12-31
0,03138 %	Beddow Capital Management Inc.	17 500	5 000	2022-12-31
0,03107 %	Private Advisor Group LLC	17 325	0	2022-12-31
0,02937 %	Morgan Stanley & Co. LLC	16 377	−18 062	2022-12-31
0,02816 %	Commonwealth Financial Network	15 700	15 700	2022-12-31
0,02376 %	Moloney Securities Asset Management, LLC	13 250	13 250	2022-12-31
0,02291 %	Formidable Asset Management, LLC	12 775	1 100	2022-12-31
0,02180 %	Advisor Group, Inc	12 155	0	2022-12-31
0,02009 %	PGIM Quantitative Solutions LLC	11 200	11 200	2022-12-31
0,01980 %	BNY Mellon Asset Management	11 043	0	2022-12-31
0,01973 %	Platform Technology Partners LLC	11 000	0	2022-12-31
0,01973 %	Consilium Associates	11 000	0	2022-12-31
0,01925 %	Oppenheimer Asset Management Inc.	10 733	0	2022-12-31
0,01491 %	UBS Financial Services, Inc.	8 313	−53 814	2022-12-31
0,01445 %	BlackRock Investment Management, LLC	8 059	1 070	2022-12-31
0,01445 %	Lord, Abbett & Co. LLC	8 059	0	2023-01-31
0,00812 %	Welzia Management SGIIC S.A.	4 530	4 530	2021-12-31
0,00770 %	Tower Research Capital LLC	4 291	−33 009	2022-12-31
0,00763 %	Amalgamated Financial Corp.	4 256	4 256	2022-03-31
0,00702 %	Simplex Trading, LLC	3 916	−15	2022-12-31
0,00511 %	Belvedere Trading, LLC	2 851	2 851	2022-12-31
0,00497 %	Federated Hermes MDTA LLC	2 774	1 622	2022-12-31
0,00400 %	Principal Funds, Inc.	2 229	−881	2022-04-30
0,00349 %	Mackenzie Financial Corporation	1 946	−253	2022-09-30
0,00320 %	C. M. Bidwell & Associates, Ltd.	1 785	1 040	2022-12-31
0,00284 %	Independent Financial Partners	1 585	0	2022-12-31
0,00263 %	BNP Paribas Securities Corp. North America	1 468	996	2022-12-31
0,00252 %	J.P. Morgan Securities plc	1 407	−2 351	2022-12-31
0,00239 %	Westfield Capital Management Company, L.P.	1 332	0	2021-09-30
0,00226 %	GF Fund Management Co., Ltd.	1 262	512	2022-06-30
0,00215 %	Antonetti Capital Management, LLC	1 200	0	2022-12-31
0,00135 %	Larson Financial Group LLC	751	0	2022-12-31
0,00110 %	Money Concepts Capital Corp	613	−45 977	2022-12-31
0,00108 %	FMP Wealth Advisers	600	100	2022-12-31
0,00087 %	RBC Capital Markets Wealth Management	485	485	2022-12-31
0,00082 %	Tinkoff Capital OOO	455	7	2021-12-31
0,00073 %	Newbridge Capital Management	405	0	2022-12-31
0,00072 %	Wells Fargo Advisors	400	0	2022-12-31

Pavadinimas	Santykis	Dviejų savaičių koreliacija	Vieno mėnesio koreliacija	Trymėnesio koreliacija	Šešių mėnesių koreliacija	Vienmečio koreliacija	Dviejų metų koreliacija
Roche Holding	TiekėjasKlientas	0,67	0,79	-0,45	0,10	-0,37	-0,72
Novartis	TiekėjasKlientas	0,58	0,65	-0,77	-0,76	-0,17	-0,08
Vaccinex	TiekėjasKlientas	-0,13	0,71	0,45	0,10	0,77	0,24
GlaxoSmithKline	TiekėjasKlientas	-0,20	0,28	-0,73	-0,58	-0,85	-0,82
Merck & Co	TiekėjasKlientas	-0,49	-0,76	-0,79	-0,77	-0,45	-0,52

What values and corporate philosophy does Surface Oncology represent?

Surface Oncology Inc is dedicated to revolutionizing cancer care through innovative therapies. The company's values revolve around scientific excellence, integrity, patient-centric approach, and collaboration. Surface Oncology is committed to discovering and developing breakthrough treatments that target the immune system to combat cancer. Their corporate philosophy emphasizes teamwork, fostering a culture of innovation, and translating scientific discoveries into potential treatments for patients in need. By combining cutting-edge science with a deep understanding of oncology, Surface Oncology strives to make a significant impact in improving outcomes for cancer patients.

In which countries and regions is Surface Oncology primarily present?

Surface Oncology Inc is primarily present in the United States.

What significant milestones has the company Surface Oncology achieved?

Surface Oncology Inc has achieved several significant milestones. The company has successfully advanced its pipeline of novel cancer immunotherapies, demonstrating promising results in preclinical and clinical trials. Surface Oncology Inc has also forged strategic collaborations with leading biopharmaceutical companies, enhancing their research and development capabilities. In addition, the company has achieved key regulatory milestones, including FDA Fast Track designation for certain drug candidates. Surface Oncology Inc continues to make substantial progress in innovating and advancing therapies to combat cancer, solidifying its position as a frontrunner in the field of oncology research and development.

What is the history and background of the company Surface Oncology?

Surface Oncology Inc, a renowned biopharmaceutical company, was founded in 2014. With a focus on developing innovative cancer therapies, Surface Oncology aims to improve the lives of patients worldwide. The company's cutting-edge approach in immunotherapy and precision medicine sets them apart in the industry. Surface Oncology collaborates with leading scientific experts and utilizes state-of-the-art technologies to identify novel targets and develop potential treatments. Leveraging their deep understanding of the tumor microenvironment, the company has built a robust pipeline of candidates targeting various solid tumor indications. Combining their commitment to advancing cancer research with their talented team and strategic partnerships, Surface Oncology remains dedicated to transforming the lives of cancer patients.

Who are the main competitors of Surface Oncology in the market?

The main competitors of Surface Oncology Inc in the market are other companies within the oncology sector. Some significant competitors include: 1. Merck & Co., Inc - a global pharmaceutical company with a strong presence in oncology treatments. 2. Roche Holding AG - a Swiss multinational healthcare company known for its innovative oncology therapies. 3. Bristol-Myers Squibb Company - a leading biopharmaceutical company focusing on cancer research and treatments. 4. AstraZeneca PLC - a British-Swedish multinational pharmaceutical company with a diverse portfolio of oncology drugs. 5. Novartis AG - a multinational pharmaceutical company with oncology treatments as a key focus area. 6. Pfizer Inc - a prominent pharmaceutical company known for its innovative cancer therapies. These competitors play a significant role in the market and compete with Surface Oncology Inc in developing and commercializing oncology treatments.

In which industries is Surface Oncology primarily active?

Surface Oncology Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Surface Oncology?

The business model of Surface Oncology Inc. revolves around developing and commercializing innovative cancer immunotherapies. Surface Oncology Inc. focuses on harnessing the immune system to target and eliminate cancer cells. The company utilizes its proprietary platform to identify and validate potential therapeutic targets, followed by the development of antibody-based therapies. Surface Oncology Inc. actively engages in strategic collaborations to advance its drug candidates and expand its pipeline. By leveraging its expertise in immunology and oncology, Surface Oncology Inc. aims to deliver novel treatment options for patients battling various types of cancer.

Koks yra Surface Oncology 2025 KGV?

P/E santykio šiuo metu Surface Oncology apskaičiuoti negalima.

Koks Surface Oncology 2025 KUV?

KUV šiuo metu negali būti apskaičiuotas Surface Oncology.

Koks yra Surface Oncology AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis Surface Oncology yra 2/10.

Koks yra Surface Oncology 2025 pajamų dydis?

tikėtina Surface Oncology pardavimai yra 7,95 mln. USD.

Kokia yra Surface Oncology 2025 pelnas?

tikėtina Surface Oncology pelnas yra −47,69 mln. USD.

Ką daro Surface Oncology?

Surface Oncology Inc is a biopharmaceutical company specializing in the discovery and development of new therapy options for cancer. The company has a strong research and development team focused on identifying novel therapeutic targets and implementing them into new therapeutics. The business models of Surface Oncology are divided into two areas: clinical development and preclinical development. Clinical development is carried out through collaborations with various biopharmaceutical companies to develop new therapies for treating cancers such as lung, colon, and breast cancer. In the preclinical development area, Surface Oncology focuses on discovering new molecules and therapies that can potentially be used in later stages of clinical development. Through the discovery of new targets and the development of new technologies, the company aims to improve cancer treatment. In terms of product development, Surface Oncology strives to develop new therapeutics that stand out from currently available therapies and have higher efficacy. The company has several drug candidates in its portfolio, including SRF388, SRF617, SRF231, and SRF373, all of which are therapeutic antibodies. These potential medications target different types of cancer and are in various stages of development, from preclinical studies to clinical trials. SRF388 is a monoclonal antibody that specifically targets IL-27RA and is a promising option for cancer treatment. IL-27RA is a protein expressed by certain types of cancer and promotes inflammation in the tumor. On the other hand, SRF617 is a monoclonal antibody that specifically binds to CD39, an enzyme found on cancer cells that inhibits the body's immune system. SRF617 could play an important role in preventing the immune suppression caused by cancer cells. SRF231 is a monoclonal antibody that specifically targets CD47, a protein expressed by tumor cells that helps them evade the body's immune response. SRF231 could play an important role in combating the tumor escape mechanisms exhibited by certain types of cancer. SRF373 is a novel monoclonal antibody that aims to inhibit the activity of TGF-beta-1, a major growth factor that promotes cancer cell growth. SRF373 has the potential to redirect the body's immune system towards cancer cells and suppress tumor growth. In summary, Surface Oncology is a promising biopharmaceutical company in cancer research and development. The company aims to find new therapeutic opportunities and improve the treatment of cancer types. Through the identification of new molecules and therapies, the company aims to suppress cancer cell growth, strengthen the body's immune system, and enhance the effectiveness of cancer treatment.

Kokia yra Surface Oncology dividendė?

Surface Oncology moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Kiek kartų Surface Oncology moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota Surface Oncology arba įmonė dividendų nemoka.

Kas yra Surface Oncology ISIN?

Surface Oncology ISIN yra US86877M2098.

Kas yra Surface Oncology WKN?

Surface Oncology WKN yra A2JJ8Q.

Kas yra Surface Oncology Tickeris?

Surface Oncology akcijų simbolis yra SURF.

Kiek dividendų moka Surface Oncology?

Per paskutinius 12 mėnesių Surface Oncology išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Surface Oncology tikėtina išmokės dividendus, kurie sudarys 0 USD.

Kokia yra Surface Oncology dividendų grąža?

Surface Oncology šiuo metu yra dydžio dividendų grąža.

Kada Surface Oncology moka dividendus?

Surface Oncology moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Kokia saugi yra Surface Oncology dividendų išmokėjimas?

Surface Oncology per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Kokia yra Surface Oncology dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

Kokiame sektoriuje yra Surface Oncology?

Surface Oncology priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von Surface Oncology kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį Surface Oncology dividendą nuo 2025-10-10, kurio dydis yra 0 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2025-10-10.

Kada Surface Oncology paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2025-10-10.

Kokia buvo Surface Oncology dividendų suma 2024 metais?

2024 metais Surface Oncology išmokėjo 0 USD dividendų.

Kokia valiuta Surface Oncology moka dividendus?

Surface Oncology dividendai yra mokami USD.

Tiesioginiai išleidimai
Netiesioginės emisijos iš įsigytos energijos
Tiesioginiai išmetimai iš vertybių grandinės
CO₂ emisijos
CO₂ mažinimo strategija
Anglies energija
Atomkraft
Bandymai su gyvūnais
Pelz & Leder
Pesticidai
Palmių aliejus
Tabakas
Genetinė inžinerija
Klimato koncepcija
Tvarioji miškininkystė
Perdirbimo nuostatai
Aplinkai draugiška pakuotė
Pavojingosios medžiagos
Degalų sąnaudos ir efektyvumas
Vandens suvartojimas ir efektyvumas

Moterų dalis tarp darbuotojų
Moterų dalis valdyme
Azijietiškų darbuotojų dalis
Akcijų dalis Azijos valdyme
Hispanų/lotynų kilmės darbuotojų dalis
Hispanų/latino kilmės vadybos dalis
Akcijų turimų tamsios odos darbuotojų procentas
Juodaodžių valdymo dalis
Baltųjų darbuotojų dalis
Baltųjų valdymo dalis
Suaugusiųjų turinys
Alkoholis
Ginkluotė
Šaunamieji ginklai
Azartiniai lošimai
Karinių sutarčių
Žmogaus teisių koncepcija
Privatumo politika
Darbo ir sveikatos apsauga
Katalikiškas

Tvarumo ataskaita
Akcijų turėtojų įtraukimas
Atsiliepimo taisyklės
Kartelio teisė

Birža	Surface Oncology Akcijų kodas
FRANKFURTAS	QSOA.F
MIUNCHENAS	QSOA.MU
NASDAQ	SURF

Legendiniai investuotojai pasirenka Eulerpool.

Surface Oncology Akcija SURF

Kursas

Akcijos kaina

Akcijų kodasSURF

ISINUS86877M2098

VVPA2JJ8Q

Surface Oncology akcijų kaina

Kursas

Apžvalga

Intraday funkcija

Bendroji grąža ir santykinė kainų pokyčiai

Interpretacija ir investavimas

Surface Oncology Akcijų istorija

Surface Oncology akcijų apyvarta, EBIT, pelnas

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

Surface Oncology Pajamų, pelno ir EBIT istorija.

Surface Oncology Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

Surface Oncology Akcijos Maržos

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

Surface Oncology Maržų istorija

Surface Oncology akcijos apyvarta, EBIT, pelnas vienai akcijai

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Surface Oncology Pardavimų, pelno ir EBIT istorija vienai akcijai

Surface Oncology akcija ir akcijų analizė

Surface Oncology Pajamos pagal segmentą

Pardavimai pagal segmentą

Pardavimų pagal segmentą apžvalga

Interpretacija ir panaudojimas

Investavimo strategija

Surface Oncology Pajamos pagal segmentą

Padaryk geriausias savo gyvenimo investicijas

Surface Oncology vertinimas pagal Fair Value

Fair Value

Supratimas apie Fair Value

Pajamų pagrindu skaičiuojamas Fair Value

Apyvartos pagrindu skaičiuojamas Fair Value

Dividendų pagrindu skaičiuojamas Fair Value

Lūkesčiai ir prognozės

Palyginamoji analizė

Surface Oncology įvertinimas pagal istorinį P/E, EBIT ir P/S

Padaryk geriausias savo gyvenimo investicijas

Surface Oncology akcijų skaičius

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Padaryk geriausias savo gyvenimo investicijas

Surface Oncology Pelno prognozės

Surface Oncology Pelnų staigmenos

Eulerpool ESG reitingas Surface Oncology akcijai

Akcijų kodas
SURF

ISIN
US86877M2098

VVP
A2JJ8Q